Today: 3 February 2026
Subscribe
Browse Category

TSX:AG News 10 December 2025 - 26 December 2025

First Majestic Silver Stock (AG) in Focus on Dec. 26, 2025: Silver Hits $75, Fresh Company Catalysts, and the Latest Forecasts

First Majestic Silver Stock (AG) in Focus on Dec. 26, 2025: Silver Hits $75, Fresh Company Catalysts, and the Latest Forecasts

Dec. 26, 2025 — First Majestic Silver Corp. stock is back in the spotlight as silver prices punch through a psychological (and headline-generating) milestone: $75 per ounce for the first time. Reuters For First Majestic Silver Corp. (NYSE: AG; TSX: AG)—often viewed as a high‑beta way to express a view on silver—the setup matters: when the metal moves sharply, miners…
26 December 2025
······
First Majestic Silver (AG) Stock Soars with Silver’s Record Rally: Q3 2025 Results, $350M Notes and 2026 Forecasts

First Majestic Silver (AG) Stock Soars with Silver’s Record Rally: Q3 2025 Results, $350M Notes and 2026 Forecasts

As silver breaks through historic price levels in December 2025, First Majestic Silver Corp. (NYSE: AG; TSX: AG) has turned into one of the market’s most aggressive ways to bet on the metal. As of 10 December 2025, First Majestic Silver stock is trading around $15.4 per share on the NYSE, near the top of its 52‑week range of roughly…
10 December 2025
······

Stock Market Today

  • Australian Shares Climb After RBA Rate Hike; Credit Corp Earnings Flat, Revenue Up
    February 3, 2026, 1:48 AM EST. Australian shares rose 0.89% as the Reserve Bank of Australia raised interest rates by 25 basis points to 3.85%, marking its first hike since 2023 amid persistent inflation. The S&P/ASX 200 closed at 8,857.10. Gold prices rebounded sharply, rising about 3% to $4,820 an ounce. Meanwhile, total dwelling approvals dropped nearly 15% in December. Credit Corp Group reported flat fiscal first-half earnings at AU$0.641 per share but saw revenue increase to AU$283.6 million; shares fell 16%. NRW Holdings secured a AU$175 million contract with Rio Tinto, boosting its shares by 5%. Neuren Pharmaceuticals' shares fell 9% after the European Medicines Agency issued a negative recommendation for its Rett syndrome drug trofinetide.
Go toTop